Crown Bioscience Expands Genomics and Next Generation Sequencing (NGS) Capabilities To Streamline Translational Biomarker Discovery Workflows
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers," said Henry Li, PhD, chief scientific officer at CrownBio. "This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments."
"Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data," said Sheng Guo, PhD, head of bioinformatics at CrownBio. "These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SAN DIEGO -- Businesswire -- Crown Bioscience, a JSR Life Sciences company, today announced the expansion of their state-of-the-art NGS capabilities, together with the launch of proprietary NGS panel services, providing increased opportunities for pharmaceutical partners to better understand drug mechanisms of action (MOA) and to develop predictive biomarkers for their investigational drug candidates.
The newly built, comprehensive suite of NGS capabilities provides clients with a streamlined multi-omics workflow of high-quality services, enabling full genomic understanding, including global gene expression, mutations, and genomic structures. This is a significant addition to CrownBio’s current preclinical and translational services, allowing clients greater insight into disease mechanisms, drug MOAs, and responder patient populations, to ultimately accelerate successful development of effective therapies.
The expanded services have been established at the Company’s Center of Translational Science in Suzhou, China, to meet increased client demand for whole genome sequencing (WGS), including Illumina’s Novaseq 6000 and BGI’s MGISEQ-2000 second generation sequencing platform. PacBio’s third generation Sequel Ⅱ sequencing platform allows for high throughput, high accuracy long-read NGS, and Bionano’s Saphyr® Genome Imaging enables large structural variant analysis and genome mapping. Comprehensive data analysis pipelines have also been built, together offering highly sensitive genome assembly and discovery algorithms.
“With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers,” said Henry Li, PhD, chief scientific officer at CrownBio. “This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments.”
In addition to the validated commercial platforms, CrownBio has also developed various powerful biomedical applications using NGS platforms, including NGS panels for bio-sample authentication, contamination detection and quantification, mouse tumor microenvironment profiling and metagenomic sequencing services for microbiome analysis. Custom NGS services are also available for clients who wish to utilize CrownBio’s expertise and large model biobank.
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,” said Sheng Guo, PhD, head of bioinformatics at CrownBio. “These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services.”
These NGS services are available for client use immediately including our newly launched mouse I/O profiling targeted RNA-seq panel. The panel will allow deep profiling of the immunogenomics of murine tumor-immune interactions through the measurement of 1080 transcripts from a single sample.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
· https://www.crownbio.com · https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210110005013/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Crown Bioscience Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- NHN KCP, 경기도형 오픈이노베이션 사업 참여… 스타트업과 성장 동력 모색 - 뉴스와이어
- 투썸플레이스, 비비×투썸 ‘달디단 밤양갱’ 음료 여름 한정 론칭 - 뉴스와이어
- 엔비피헬스케어, 특허청 ‘지식 재산 경영 인증’ 획득… 국내외 특허등록 95건 돌파 - 뉴스와이
- 다시 깨어난 3500억 숙취해소제 시장… 스틱형 성장세 주목 - 뉴스와이어
- 현대자동차, ST1 카고 및 카고 냉동 출시 - 뉴스와이어
- 대웅제약 펙수클루, 1분기 처방액 57% 성장… 3세대 위장약 P-CAB 성장 이끌어 - 뉴스와이어
- 롯데건설 ‘계양 롯데캐슬 파크시티’ 26일 견본주택 오픈 - 뉴스와이어
- 한글 문화상품의 매력을 세계에 알린다 - 뉴스와이어
- 비즈니스북스 ‘1천만 원으로 시작하는 수도권 아파트 투자의 기적’ 출간 - 뉴스와이어
- 죽향 이생강 명인 ‘구전심수 82년 젓대소리’ 공연 열어 - 뉴스와이어